Team
health

APRI Calculator

The APRI (Aspartate Aminotransferase to Platelet Ratio Index) score is a non-invasive marker that estimates hepatic fibrosis severity using two routine blood tests: AST enzyme levels and platelet count. Hepatologists and primary care physicians use APRI to stratify patients with chronic liver disease without resorting to biopsy, making it invaluable for monitoring viral hepatitis, alcoholic liver disease, and metabolic dysfunction-associated fatty liver disease (MAFLD).

Last updated:

Creators Adena Benn, BSc
8,977 people find this calculator helpful

Understanding the APRI Score

Liver biopsy remains the gold standard for diagnosing fibrosis, but it carries risks of bleeding, infection, and patient discomfort. The APRI index emerged as a practical alternative, leveraging two inexpensive, routinely measured laboratory values to estimate fibrosis stage.

AST (aspartate aminotransferase) is an enzyme found primarily in liver cells. When hepatic tissue is damaged, AST leaks into the bloodstream. Platelet count, meanwhile, falls as cirrhosis develops because the spleen becomes enlarged and sequesters platelets. By combining these inverse relationships—high AST and low platelets suggest advanced disease—the APRI score captures a snapshot of liver health.

Originally validated in patients with chronic hepatitis C, APRI has since proven useful across multiple etiologies: hepatitis B, autoimmune hepatitis, NAFLD, and alcohol-related liver disease. It is particularly valuable in resource-limited settings and for longitudinal monitoring.

APRI Calculation Formula

The APRI score normalizes the AST level to a reference upper limit (typically 40 IU/L) and divides by platelet count (in units of 10⁹/L), then multiplies by 100 for convenience:

APRI = [(AST ÷ AST upper limit) ÷ Platelet count] × 100

  • AST — Serum aspartate aminotransferase level (IU/L)
  • AST upper limit — Reference upper limit of normal AST; typically 40 IU/L but may vary by laboratory
  • Platelet count — Platelet count in units of 10⁹/L (or 10³/µL)

APRI Score Interpretation & Clinical Thresholds

APRI thresholds help clinicians stage fibrosis risk:

  • APRI < 0.5: Low probability of significant fibrosis (F ≥ 2)
  • APRI 0.5–0.7: Intermediate risk; further evaluation recommended
  • APRI ≥ 0.7: Significant fibrosis likely (sensitivity 77%, specificity 72%)
  • APRI ≥ 1.0: Severe fibrosis or cirrhosis (sensitivity 76%, specificity 72%)

These cutoffs derive from large cohorts of hepatitis C patients but generalise reasonably well to other chronic liver diseases. Importantly, a single APRI measurement is a snapshot; serial measurements over months or years strengthen clinical interpretation. An APRI rising over time signals progressive fibrosis, warranting intensified monitoring or intervention.

Practical Considerations When Using APRI

Several factors can skew APRI results and must be weighed against the score itself.

  1. Lab variability and timing — AST fluctuates with inflammation, haemolysis, and even strenuous exercise. Platelet counts vary with infection, medications, and alcohol use. For reliable APRI, obtain blood samples during stable clinical conditions, preferably fasting and when the patient has been haemodynamically stable for several days.
  2. Age and sex effects — APRI performance varies by patient demographics. Older adults and women may have lower platelet counts and different AST references, potentially inflating APRI falsely. Always interpret APRI alongside clinical context rather than as a standalone diagnosis.
  3. Disease-specific limitations — APRI was developed for hepatitis C; its accuracy in NAFLD, autoimmune hepatitis, and primary biliary cholangitis is lower. In conditions where AST elevation is modest or platelets remain normal despite fibrosis, APRI may underestimate disease severity.
  4. Not a replacement for imaging — While APRI avoids biopsy risks, it cannot detect early cirrhosis complications, varices, or hepatocellular carcinoma. Use APRI as a screening tool; abnormal scores warrant ultrasonography, elastography (fibroscan), or specialist referral for confirmation.

Worked Example: Calculating APRI Step-by-Step

Consider a patient with AST 110 IU/L, AST upper limit 40 IU/L, and platelet count 110 × 10⁹/L:

Step 1: Divide AST by the upper limit: 110 ÷ 40 = 2.75

Step 2: Divide the result by platelet count: 2.75 ÷ 110 = 0.025

Step 3: Multiply by 100: 0.025 × 100 = 2.5

An APRI of 2.5 exceeds the threshold of 1.0, indicating high likelihood of cirrhosis. This patient would benefit from urgent hepatology consultation, imaging, and potentially life-prolonging interventions such as antiviral therapy or liver transplant evaluation.

Frequently Asked Questions

What is the difference between APRI and FIB-4 score?

Both APRI and FIB-4 are non-invasive fibrosis markers using routine labs, but they differ in construction. APRI uses AST and platelets; FIB-4 incorporates age, AST, and platelets. FIB-4 tends to perform better in NAFLD and older populations, while APRI remains the standard in viral hepatitis. Many clinicians use both scores together—concordant results strengthen confidence in fibrosis staging, while discordant scores prompt further investigation.

Can APRI detect early-stage liver disease before symptoms appear?

APRI can identify fibrosis in asymptomatic patients, making it useful for screening high-risk groups (chronic hepatitis B carriers, heavy alcohol users, those with elevated liver enzymes). However, APRI reflects established parenchymal damage; it will not detect early inflammation or steatosis before fibrosis develops. Coupled with ultrasound and liver function tests, APRI helps identify subclinical disease early enough to initiate treatment.

Should I repeat APRI testing, and how often?

Serial APRI measurements are more informative than a single score. In stable patients with low APRI, annual or biennial testing suffices. In those with intermediate or high APRI, or when starting antiviral therapy, repeat testing every 3–6 months helps track progression or response. Rapid APRI decline often reflects improved inflammation rather than regression of established fibrosis.

Why might my APRI score be high despite feeling well?

APRI reflects objective biochemical markers, not symptoms. Many patients with significant fibrosis or early cirrhosis feel completely well until decompensation occurs (bleeding, ascites, encephalopathy). A high APRI mandates investigation even in asymptomatic individuals. This underscores why screening in at-risk populations—those with chronic hepatitis, obesity, or heavy alcohol use—is crucial.

What if my AST and platelet counts are both normal?

Normal AST and platelet count typically yield a low APRI (< 0.5), suggesting minimal fibrosis. However, this does not exclude early inflammation or steatosis. In patients with newly detected liver disease and normal APRI, ultrasound and transient elastography clarify the stage. Conversely, progressive fibrosis can sometimes occur with normal AST; elastography is more sensitive in such cases.

Can APRI be used to monitor response to treatment?

Yes. In patients receiving antivirals for hepatitis B or C, or those reducing alcohol intake, APRI often improves as inflammation subsides. A falling APRI over 6–12 months indicates favourable response. However, established cirrhosis (bridging fibrosis and cirrhosis) regresses slowly or not at all even after viral clearance, so APRI may remain elevated despite cure. Elastography or imaging provides complementary data on structural improvement.

More health calculators (see all)

Body Roundness Index Calculator Arterial Blood pH Calculator Weight Gain Calculator Infant Tylenol Dosage Calculator Smoking Recovery Calculator Fetal Weight Percentile Calculator Shock Index Calculator Duke Activity Status Index (DASI) Calculator